PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues

• Published in: Bioorganic chemistry 2024-06, Vol.147, p.107323-107323, Article 107323
• Main Authors: Yevale, Digambar, Teraiya, Nishith, Lalwani, Twinkle, Dalasaniya, Mayur, Kapadiya, Khushal, Ameta, Rakesh Kumar, Sangani, Chetan B., Duan, Yong-Tao
• Format: Article
• Language: English
• Subjects: Apoptosis; Docking; Metabolic stability; PI3Kδ/mTOR inhibitors
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2024.107323

[Display omitted] •Designed compounds demonstrated selective cytotoxicity against cancer cell lines.•Induction of apoptosis and dual PI3Kδ/mTOR inhibition caused anticancer effects.•Anticancer mechanisms were proven via the PAM signaling cascade and the intrinsic apoptosis pathways.•Inhibition of PI3Kδ/mTOR correlates with the docking study of the compound 5 h.•Compound 5 h demonstrated exceptional in vitro metabolic stability. Phosphatidylinositide-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) have recently been identified as potential cancer targets. In our work, a new family of quinoline analogues was designed, developed, and evaluated as dual inhibitors of PI3Kδ/mTOR. The preliminary biological activity analysis led to the discovery of the lead compounds 5h and 5e. Compounds 5h and 5e exhibited excellent anti-tumor potency with IC50 of 0.26 µM and 0.34 µM against Ramos cells, respectively. Importantly, based on the enzymatic activity assay results, compounds 5h and 5e were identified as dual inhibitors of PI3Kδ and mTOR, with IC50 values of 0.042 µM and 0.056 µM for PI3Kδ and 0.059 µM and 0.073 µM for mTOR, respectively. Furthermore, these compounds showed superior selectivity for blocking PI3Kδ compared to other PI3K isoforms (α, β, and γ), supporting the concept of developing inhibitors that specifically target PI3Kδ/mTOR. The most effective compound 5h was chosen for additional biological testing. At a low dose of 0.5 µM, a western blot investigation confirmed the anticancer effects by inhibiting the PAM cascade, which in turn reduced downstream biomarkers pAkt (Ser473), pAkt (Thr308), and pRPS6 (Ser235/236). Furthermore, it increased apoptosis at the early (10.03 times) and late (17.95 times) stages in the Annexin-V assay as compared to the standard. In addition, the expression of p53, caspase-3, caspase-9, and the Bax/BCl-2 ratio were all significantly increased by compound 5h in the ELISA assay. Based on these results, it appears that 5h may activate the intrinsic apoptosis pathway, which in turn triggers cell death. Furthermore, the anticancer effects could be attributed to the inhibition of PI3Kδ/mTOR, as shown by docking interactions. Lastly, it demonstrated improved in vitro metabolic stability and passed the in silico ADMET/drug-likeness test. This profile recommends 5h for future in vivo PK-PD and efficacy investigations in animal cancer models.